# Non-Selective (β₁ + β₂) Blockers

## Examples

- **First generation (non-selective):**
  - `propranolol`
  - `nadolol`
  - `timolol`
  - `sotalol` _(also class III antiarrhythmic)_
  - `pindolol` _(partial agonist / ISA)_
  - `penbutolol`
  - `carteolol`

> They **lower BP**, **protect heart**, but cause **bronchospasm** and **metabolic risks** — hence **cardioselective β₁-blockers** are preferred in most hypertensive patients.

## Mechanism of Action (MOA)

- Competitively block **β₁ and β₂ adrenoceptors** in heart, vessels, bronchi, pancreas, and other tissues.
- **β₁ blockade →**
  - ↓ HR (negative chronotropic)
  - ↓ myocardial contractility (negative inotropic)
  - ↓ cardiac output
  - ↓ renin release from juxtaglomerular cells

- **β₂ blockade →**
  - ↑ bronchial & vascular smooth muscle tone (bronchoconstriction)
  - ↓ glycogenolysis and gluconeogenesis (risk of hypoglycemia)

- Overall: **↓ BP due to fall in CO and renin activity** (long-term due to ↓ TPR).

## Pharmacodynamics (Effects)

| System          | Effect                                                            |
| :-------------- | :---------------------------------------------------------------- |
| **Cardiac**     | ↓ HR, ↓ contractility, ↓ CO, ↓ myocardial O₂ demand               |
| **Vascular**    | Acute: may ↑ TPR (β₂ block); chronic: ↓ TPR                       |
| **Renal**       | ↓ Renin release → ↓ Ang II & aldosterone                          |
| **CNS**         | Sedation, fatigue (lipophilic drugs like `propranolol` cross BBB) |
| **Respiratory** | Bronchoconstriction (β₂ block)                                    |
| **Metabolic**   | Inhibit lipolysis, glycogenolysis; mask hypoglycemia symptoms     |

## Pharmacokinetics

| Drug                          | Notes                                                                                                          |
| :---------------------------- | :------------------------------------------------------------------------------------------------------------- |
| **`Propranolol`**             | Highly lipophilic → good oral absorption but high first-pass metabolism; short half-life (3–5 h). Crosses BBB. |
| **`Nadolol`**                 | Long-acting; excreted unchanged in urine; less CNS effect.                                                     |
| **`Timolol`**                 | Used systemically and topically for glaucoma.                                                                  |
| **`Pindolol` / `Penbutolol`** | Have **intrinsic sympathomimetic activity (ISA)** → less bradycardia.                                          |

## Indications

- **Hypertension** (esp. with high sympathetic activity)
- **Angina pectoris** — ↓ O₂ demand
- **Cardiac arrhythmias** (esp. SVT, digitalis-induced, sotalol for VT)
- **Myocardial infarction (post-MI)** — ↓ reinfarction and mortality
- **Hypertrophic obstructive cardiomyopathy**
- **Migraine prophylaxis** (`propranolol`)
- **Thyrotoxicosis** (symptomatic relief, ↓ T₄→T₃ conversion)
- **Essential tremor**
- **Pheochromocytoma (with α-blocker)** — _never alone!_
- **Glaucoma** (`timolol` topical)

## Adverse Effects

| System             | Effect / Explanation                                                                |
| :----------------- | :---------------------------------------------------------------------------------- |
| **Cardiovascular** | Bradycardia, AV block, hypotension, heart failure exacerbation                      |
| **Respiratory**    | **Bronchospasm** — dangerous in asthma / COPD                                       |
| **CNS**            | Fatigue, depression, sleep disturbances, nightmares (lipophilic agents)             |
| **Metabolic**      | Mask hypoglycemia signs (tachycardia) in diabetics; may cause hyperglycemia & ↑ TGs |
| **Vascular**       | Cold extremities, Raynaud’s phenomenon                                              |
| **Withdrawal**     | Rebound hypertension / angina if stopped abruptly (β-receptor upregulation)         |

## Cautions

- **Asthma / COPD** — risk of bronchospasm.
- **Diabetes mellitus** — masks hypoglycemia; monitor glucose.
- **Peripheral vascular disease** — may worsen.
- **Bradycardia or AV block** — avoid or monitor closely.
- **Abrupt withdrawal** — avoid; taper dose.

## Contraindications

- **Bronchial asthma / severe COPD.**
- **Severe bradycardia, heart block, or sick-sinus syndrome.**
- **Overt cardiac failure (acute).**
- **Severe peripheral arterial disease.**
- **Uncontrolled diabetes (relative).**

## Key Points Summary

| Feature              | Non-Selective β-Blockers                                   |
| :------------------- | :--------------------------------------------------------- |
| β-Receptor activity  | Block both β₁ and β₂                                       |
| Major cardiac effect | ↓ HR, ↓ CO, ↓ renin                                        |
| Major adverse risk   | Bronchospasm, hypoglycemia masking                         |
| Lipid solubility     | High for `propranolol` → CNS effects                       |
| Clinical use         | Hypertension, angina, arrhythmia, migraine, thyrotoxicosis |
| Contraindicated in   | Asthma, AV block, bradycardia                              |
